Ratings Bausch Health Companies Inc. Toronto S.E.

Equities

BHC

CA0717341071

Market Closed - Toronto S.E. Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
11.92 ^CAD	+1.10%		-0.17%	+12.14%

04-25	Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	MT
04-25	Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company's attractive earnings multiples are brought to light by a P/E ratio at 13.25 for the current year.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company does not generate enough profits, which is an alarming weak point.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
BAUSCH HEALTH COMPANIES INC.	+12.14%	3.19B	-
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
NOVARTIS AG	+5.46%	200B	B-
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes